But Tevimbra’s role looks shaky as adverse events loom.
ApexOnco Front Page
Recent articles
JP Morgan approaches.
Global phase 2 data in TNBC look similar to earlier results in China.
Pfizer reveals the discontinuation of PF-08046044.
Studies presented at ASH show this to be true only up to a point.
Linker-MM4 data raise more questions about sequencing of therapies for multiple myeloma.
Tecvayli plus Darzalex could challenge Carvykti in the push for a functional cure.
The company might have blown Enliven out of the water.
